DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Imaging Biomarkers of Progression of Mobility Impairment in Parkinson's Disease (PD)

Information source: Department of Veterans Affairs
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Parkinson's Disease

Phase: N/A

Status: Completed

Sponsored by: Department of Veterans Affairs

Official(s) and/or principal investigator(s):
Nicolaas I Bohnen, MD PhD, Principal Investigator, Affiliation: VA Ann Arbor Healthcare System, Ann Arbor, MI


The purpose of this research is to evaluate possible reasons why people with Parkinson's disease tend to fall more often. Parkinson's disease is a disease where persons have slowness in movements and walking as well as symptoms of shaking. You are being asked to participate in this study because you previously participated as a person with Parkinson's or as a normal comparison subject in a similar imaging study about 3-4 years ago. The previous research study evaluated functions of memory, thinking, walking and how these relate to the measurement of certain chemicals (acetylcholine and dopamine) in the brain using an imaging procedure called positron emission tomography (PET). You may know that the brain chemical dopamine, a "neurotransmitter" substance (a chemical messenger that nerve cells need to communicate with each other), is important for the brain to control movements and that the brain chemical acetylcholine may have functions related to mental concentration and attention. You are now being asked for a new study as a follow-up about 3 years after the previous study. The main purpose of the follow-up study is to determine which of the two brain chemicals (dopamine, acetylcholine) or changes seen on brain MR called "small vessel disease" (which is commonly seen with aging) are related to development of balance problems. The study activities are very similar as the previous study you participated in.

Clinical Details

Official title: Imaging Biomarkers of Progression of Mobility Impairment in PD

Study design: Observational Model: Cohort, Time Perspective: Prospective

Primary outcome: PET and MRI neuroimaging


Minimum age: 50 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Patients who meet the UK Parkinson's Disease Society Brain Bank Research Center

clinical diagnostic criteria for PD.

- Hoehn and Yahr stages 1-2. 5 at initial recruitment in baseline study.

- Absence of dementia confirmed by neuropsychological testing at initial recruitment in

baseline study. Exclusion Criteria:

- contra-indication for magnetic resonance study

- Pregnancy or breastfeeding

Locations and Contacts

VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor, Michigan 48105, United States
Additional Information

Click here for more information about this study: Imaging Biomarkers of Progression of Mobility Impairment in PD

Starting date: May 2010
Last updated: March 5, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017